- The new microbiology laboratory and sterility testing suite are designed for GMP drug product applications.
- This addition is part of the broader Lexington expansion and includes a dedicated sterility testing isolator, three new biosafety cabinets, and enhanced laboratory capacity.
- The remainder of the expansion, including commercial-scale fill/finish, is expected to be online in late 2027.
MUMBAI, India, Oct. 6, 2026 /PRNewswire/ -- Piramal Pharma Solutions ("PPS"), a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. ("PPL") (NSE: PPLPHARMA) (BSE: 543635), has opened a new microbiology laboratory at its sterile injectable facility in Lexington, Kentucky. This addition marks a significant step forward in PPS' ongoing $85 million Lexington expansion, aimed at enhancing commercial-scale capabilities and improving operational efficiency. The new laboratory was released for routine GMP use on September 11, 2026, and shortly thereafter, its new sterility testing suite was conditionally approved, making the lab one of the first major components to come online in the expansion. The full manufacturing expansion is expected to be operational in late 2027.
The new lab more than triples the site's existing microbiology testing space, supporting improved laboratory workflow and providing additional capacity to accommodate future growth. The added space features three new biosafety cabinets, allowing PPS to run concurrent tests and reduce sample queue times. All incubators have also been consolidated within the new lab, further streamlining workflow and improving monitoring and accessibility across testing activities.
A key element of the lab is a dedicated sterility testing suite with a Grade C background environment, representing a major upgrade from the previously non-classified area. At its center is a fully integrated, Grade A sterility testing isolator that doubles the site's sterility testing capacity and allows multiple samples to be processed simultaneously. By supporting both open and closed filtration methods, the new isolator provides greater flexibility to meet a wider range of product testing requirements. The area also includes built-in pass-throughs to move samples directly from the manufacturing floor to the lab, reducing contamination risk and protecting product integrity.
These enhancements are expected to reduce testing times by up to 50%, accelerating batch releases, minimizing bottlenecks, and smoothing transitions as programs move from clinical to commercial stages. The new infrastructure also reinforces the site's contamination control and sterility assurance capabilities, while the added capacity reduces supply risk and prepares the site for commercial-scale demand.
"The new microbiology laboratory represents an important milestone in our Lexington expansion journey," said Nathan Richardson, VP and Site Head, Piramal Pharma Solutions Lexington. "By enhancing sterility testing and microbiological quality capabilities, we are further strengthening our ability to support clients with high quality, reliable, and responsive services throughout the product life cycle. This investment reflects our continued commitment to operational excellence, patient safety, and the future growth of sterile injectable manufacturing in Lexington."
The new microbiology lab solidifies PPS' position as a leader in sterile injectables, empowering Lexington to deliver high quality, reliable, and patient-focused services to small molecule, bioconjugate, and peptide modality clients worldwide.
About Piramal Pharma Solutions
Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including drug discovery solutions, process and pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. We also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's subsidiary, Yapan Bio Private Limited.
For more information visit: Piramal Pharma Solutions | LinkedIn| Facebook | X
About Piramal Pharma Limited
Piramal Pharma Limited (PPL) (NSE: PPLPHARMA) (BSE: 543635), offers a portfolio of differentiated products and services through its 17 global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the Piramal Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market.
For more information, visit: Piramal Pharma | LinkedIn
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Piramal Pharma Solutions Launches New Microbiology Laboratory at Its Lexington, KY Sterile Injectable Facility
Piramal Pharma Solutions Launches New Microbiology Laboratory at Its Lexington, KY Sterile Injectable Facility
Piramal Pharma Solutions Launches New Microbiology Laboratory at Its Lexington, KY Sterile Injectable Facility
Local cuisine emerges as the region's strongest dining force, as traditional restaurant settings give way to fluid, social spaces
SINGAPORE, Oct. 6, 2026 /PRNewswire/ -- Marriott International has unveiled Future of Food 2027, its latest report exploring food and beverage trends across Asia Pacific excluding China. Drawing on conversations with leading chefs, hospitality experts and regional influencers, alongside insights from Marriott International properties across the region, the report reveals a pivotal transformation: the rise of place. As dining breaks free from traditional restaurant boundaries into fluid, social formats, diners increasingly seek experiences that are hyper-local, authentic and deeply connected to their destination.
Across Asia Pacific excluding China, diners are increasingly seeking authenticity and connection. Demand for authentic local signature dishes is surging, with 95% of surveyed properties identifying this as the biggest trend in their market. At the same time, dining is no longer confined to the traditional restaurant setting. Guests are gathering across bars, lounges, counters and flexible spaces, turning hotels into social and cultural hubs where guests move fluidly throughout the day. The result is a new era of dining where the story behind what people eat and where they eat matters more than ever.
"Across Asia Pacific, we're witnessing a shift toward intimate, locally-rooted experiences, where smaller, intentional spaces replace traditional formal dining models," said Petr Raba, Vice President of Food & Beverage, Marriott International, Asia Pacific excluding China. "Hotels are becoming cultural storytellers, embedding regional talent, locally sourced ingredients and authentic connection into every aspect of the dining experience to create spaces that feel distinctly of their place."
Key Trends Shaping the Future of Food
- The Spatial Shift
Dining is moving beyond the traditional restaurant model as guests increasingly lean toward more flexible, social and experience-led spaces. Across Asia Pacific excluding China, nearly half of the surveyed properties report a growing demand for casual venues such as lounges, bars and outdoor settings, while emerging concepts are embracing intimate 40 to 60-seat footprints with distinct identities. In Vietnam, 71% of surveyed properties report growth in bar and lounge dining, reflecting the growing appeal of more fluid dining experiences. An invisible layer of technology is supporting this shift, with AI enhancing everything from menu development and marketing to staffing and guest insights, allowing teams to focus on delivering more personalized hospitality. 100% of restaurants and bars surveyed in Thailand are already using AI in their operations. - The Local Advantage
Local cuisine has become the defining force shaping dining decisions across the region. Demand for authentic local signature dishes is now the strongest trend identified by 95% of the surveyed properties and outweighing value for money when guests choose where to dine. Hotels are responding by building menus around ingredients and stories rooted in their destinations. At Hearth at The Ritz-Carlton, Perth, for example, a signature dish featuring local Wagin duck showcases Western Australia's produce while reflecting the restaurant's seasonal, locally driven philosophy. Over the past year, four in five properties have introduced new local ingredients from Kyoto vegetables in Japan to Kampot sea salt in Cambodia-inspired menus and indigenous spices across Southeast Asia, while nearly three-quarters report local ingredients appearing more frequently in beverage menus. This trend is particularly pronounced in India and Indonesia, where demand for local signature cuisine reaches 71% and 67% respectively, highlighting a growing desire for dining experiences that tell the story of a destination. - 99-Minute Fine Dining
Fine dining is undergoing a temporal revolution with up to five memorable courses delivered in under two hours, replacing four-hour tasting menus with ten-plus courses. Across the region, 58% of properties report that the average fine dining experiences last between 1.5 and 2 hours. Singapore has emerged as one of the region's fastest-paced fine dining markets with 85% of restaurants reporting an average time of 1.5 hours. Restaurants are adapting by simplifying menus, introducing more a la carte options and focusing on standout moments over the number of courses. In South Korea, one in five establishments have already reduced the number of courses served, while 30% of fine-dining restaurants in the Philippines have introduced a la carte menus. Australia sees both fewer courses and shorter service times, with the conversation shifting toward "wow moments" rather than course quantity.
Additional Report Highlights:
- Eat Well, Eating Your Age: Wellness has become a core dining consideration, with ingredients rooted in Asia Pacific's rich food traditions finding renewed relevance among modern travelers. Today, 97% of surveyed Marriott International properties in Asia Pacific excluding China serve dishes associated with health and longevity, while wellness increasingly extends beyond the plate to healthier mini-bars and wellness-focused turndown experiences.
- The Modern Menu: Across Asia Pacific, menus are becoming more expressive and multi-sensory, with texture rising alongside flavor as a defining element of the dining experience. At the same time, plant-forward dining is accelerating, prompting Marriott International to introduce its APEC Plant-Forward Program across the region in 2027, making it one of the first major global hotel groups to integrate plant-forward dining into its operational foundation permanently.
- Alcohol Alternatives: The low- and no-alcohol movement has evolved from niche trend to hospitality mainstay, with 42% of Marriott International restaurants and bars surveyed in Asia Pacific excluding China reporting increased sales of non-alcoholic beverages. From premium spirits to alcohol-free pairings, guests are increasingly seeking sophisticated alternatives without compromise.
Looking Ahead
Asia Pacific's F&B landscape is fundamentally shifting toward authenticity and intentionality. Hotels and restaurants thriving in 2027 are those that understand their place deeply - its ingredients, culture, people and design experiences around that foundation. They are creating smaller, more distinctive spaces where technology elevates genuine hospitality, while telling stories that connect guests emotionally to destination and cuisine. The result is a regional dining scene that feels less like a global template adaptation and more like a collection of distinctive, culturally rooted experiences.
About Marriott International
Marriott International, Inc. (Nasdaq: MAR) is based in Bethesda, Maryland, USA, and encompasses a portfolio of compelling brands across luxury, premium, select, midscale, extended stay, and all-inclusive, with over 10,000 properties in 148 countries and territories, as of June 30, 2026. Marriott franchises, operates, and licenses hotel, residential, timeshare, yacht, outdoor, and other lodging products all around the world. The company offers Marriott Bonvoy®, its highly awarded travel platform. For more information, please visit our website at www.marriott.com, and for the latest company news, visit www.marriottnewscenter.com. In addition, connect with us on Facebook and @MarriottIntl on X and Instagram.
Download the full Future of Food 2027 reporthere to explore the complete trends shaping Asia Pacific's culinary future.
Access high-resolution images and media assets here.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
THE RISE OF PLACE: MARRIOTT INTERNATIONAL REVEALS ASIA PACIFIC'S FUTURE OF FOOD
